Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eon Sporanox Generic Cleared To Launch By Court

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is reviewing a trial court’s ruling that it does not infringe a Janssen patent before deciding whether to launch. Eon says its 180-day exclusivity will not be triggered until commercial marketing or an appellate court decision.

You may also be interested in...



Sporanox Generic Launches

Eon launched the first generic of Janssen's antifungal Sporanox (itraconazole), the company announced Feb. 9

Sporanox Generic Launches

Eon launched the first generic of Janssen's antifungal Sporanox (itraconazole), the company announced Feb. 9

Eon Generic Sporanox Approved; Launch Will Await Ruling In Litigation With Janssen

Eon’s ANDA for itraconazole is approved with 180-day marketing exclusivity, but launch depends on the outcome of the patent case. A judge’s decision on infringement and the doctrine of equivalents is pending.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel